Verastem (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing medicines aimed at the treatment of cancer. Their operations are centered around pioneering small molecule drugs that target critical pathways in the growth and survival of cancer cells. Verastem's projects typically involve conducting clinical trials, engaging in rigorous research and development, and seeking regulatory approvals for their innovative treatments. The company’s objective is to significantly improve outcomes for patients suffering from various forms of cancer by offering new, targeted therapeutic options. Their commitment to advancing cancer treatment is evident in their pursuit of cutting-edge science and their collaboration with healthcare professionals and institutions worldwide.